Myocyte enhancer factor 2D promotes tumorigenicity in malignant glioma cells
- 133 Downloads
The prognosis of patients with malignant glioma is always quite poor, and this poor prognosis is probably due to our incomplete understanding of the molecular mechanisms underlying malignant glioma. It is known that myocyte enhancer factor-2D (MEF2D) plays an oncogenic role in hepatocellular carcinoma and promotes the survival of various types of cells. However, little is known about the expression profile and function of MEF2D in malignant glioma. In this study, we investigated the function and expression of MEF2D in malignant glioma. We found that in malignant glioma, there is an aberrantly high expression of MEF2D, which leads to poor prognosis of malignant glioma. The downregulation of MEF2D suppresses the proliferation of malignant glioma cell lines by inducing delay of S and G2/M phases of cell cycle and promoting apoptosis. Furthermore, the overexpression of MEF2D in astrocytes accelerates cell proliferation by regulating cell cycle progression. Furthermore, a mouse malignant glioma model demonstrated that MEF2D deficiency blocks malignant glioma formation in vivo. We conclude that MEF2D may act as a potential oncogene in malignant glioma and thus serve as a candidate target for malignant glioma therapy.
KeywordsMEF2D Malignant glioma Cell cycle Apoptosis
- 1.Grossman SA, Ye X, Piantadosi S, Desideri S, Nabors LB, Rosenfeld M, et al. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res. 2010;16(8):2443–9. doi: 10.1158/1078-0432.CCR-09-3106.CrossRefPubMedPubMedCentralGoogle Scholar
- 3.Okamoto S, Krainc D, Sherman K, Lipton SA. Antiapoptotic role of the p38 mitogen-activated protein kinase-myocyte enhancer factor 2 transcription factor pathway during neuronal differentiation. Proc Natl Acad Sci U S A. 2000;97(13):7561–6. doi: 10.1073/pnas.130502697.CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Prima V, Gore L, Caires A, Boomer T, Yoshinari M, Imaizumi M, et al. Cloning and functional characterization of MEF2D/DAZAP1 and DAZAP1/MEF2D fusion proteins created by a variant t (1;19) (q23;p13.3) in acute lymphoblastic leukemia. Leukemia. 2005;19(5):806–13. doi: 10.1038/sj.leu.2403684.CrossRefPubMedGoogle Scholar
- 27.Blau L, Knirsh R, Ben-Dror I, Oren S, Kuphal S, Hau P, et al. Aberrant expression of c-Jun in glioblastoma by internal ribosome entry site (IRES)-mediated translational activation. Proc Natl Acad Sci U S A. 2012;109(42):E2875–84. doi: 10.1073/pnas.1203659109.CrossRefPubMedPubMedCentralGoogle Scholar